Newsletter
Weather
Community
English home Forum Photo Gallery Features Newsletter Archive   About US Help Site Map
China
World
Opinion
Business
Sci-Edu
Culture/Life
Sports
Photos
 Services
- Newsletter
- Online Community
- China Biz Info
- News Archive
- Feedback
- Voices of Readers
- Weather Forecast
 RSS Feeds
- China 
- Business 
- World 
- Sci-Edu 
- Culture/Life 
- Sports 
- Photos 
- Most Popular 
- FM Briefings 
 Search
 About China
- China at a glance
- China in brief 2004
- Chinese history
- Constitution
- Laws & regulations
- CPC & state organs
- Ethnic minorities
- Selected Works of Deng Xiaoping

Home >> Sci-Edu
UPDATED: 08:23, December 29, 2005
Human bird flu vaccine can meet demands of large quantity production: expert
font size    

A Chinese vaccine expert said here Wednesday that China has established a store of NIBRG-14 virus strain to vaccinate against H5N1 which can meet the demands of large quantities of vaccine production.

Yin Weidong, a leading expert for China's huamn bird flu vaccine project, said the research group has made preparations to produce human-use bird flu vaccine in massive quantities.

Yin's research shows that the biological properties of the virus strain remain the same as the original even after developing a tenth generation which displays a steady inheriting process, indicating that the virus strain can be used in large quantity vaccine production.

The Beijing-based Sinovac Biotech Co Ltd. led by Yin started cooperation with the Chinese Center for Disease Control and Prevention in 2004 and successfully developed a human bird flu vaccine in November 2005 which is currently under clinical tests that will last about 12 months.

Yin said the group adopted a researching concept earlier proposed by the European Union that is to research the immunity, security and effectiveness of the dangerous "prototype" H5N1, H9N2 and H7N2.

If the virus mutates, new vaccines can be easily developed on the basis of those prototypes.

"We are capable of producing vaccines against other types of influenza if the virus develops into other forms," said Yin, who is also the managing director of Sinovac. "We can modify the virus strain within 48 days and update the human bird flu vaccine in four months after the virus mutates."

The flu virus easily mutates, which can disable any powerful vaccine, said Wang Xiaofang, director of the rural and social development department under the Ministry of Science and Technology.

Therefore, Wang said, the capability to research, develop and produce vaccines is much more important than vaccines themselves.

"Such storage of virus strains resemble duplicating machines in that we can quickly copy and update any prevailing flu virus on the basis of those established arenas," said Wang.

High-risk groups, such as poultry farm workers and medical staffers in the bird flu outbreak areas will be vaccinated as long as the vaccine passes a safety test, Yin said.

Source: Xinhua


Comments on the story Comment on the story Recommend to friends Tell a friend Print friendly Version Print friendly format Save to disk Save this


   Recommendation
- Text Version
- RSS Feeds
- China Forum
- Newsletter
- People's Comment
- Most Popular
 Related News
- China develops 1st live vaccine against bird flu

- China develops first live vaccine

- Thailand, Indonesia to share Tamiflu vaccines

- Trials of bird flu vaccine encouraging: French firm

- Official: China to provide free and easy-to-use bird flu vaccines

- China exports bird flu vaccine to Indonesia


Manufacturers, Exporters, Wholesalers - Global trade starts here.
Copyright by People's Daily Online, all rights reserved